Literature DB >> 7488018

A novel method to purify recombinant vascular endothelial growth factor (VEGF121) expressed in yeast.

D Mohanraj1, T Olson, S Ramakrishnan.   

Abstract

VEGF is a potent mitogen for vascular endothelial cells in vitro and acts as an angiogenic factor in vivo. VEGF121 differs from the other isoforms in that it lacks the heparin-binding domain. To study the potential differences in biological functions of the VEGF isoforms, we cloned and expressed VEGF121 in a yeast expression system. VEGF121 was secreted from the yeast cells as a homodimer with a molecular weight of 34-36 kDa. By taking advantage of the consecutive histidine residues present at position 11 and 12 in VEGF, a novel method of purification using Nickel affinity chromatography was developed. Since all the isoforms of VEGF have an identical amino terminal end, this method can be used to purify not only VEGF121 but also the other forms of VEGF. The level of expression achieved using this system was as high as 40 mg/L. The recombinant protein was biologically active in stimulating the in vitro proliferation of vascular endothelial cells and positively reacted to an antiserum made against recombinant VEGF165.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488018     DOI: 10.1006/bbrc.1995.2527

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis.

Authors:  Ratchada Cressey; Onusa Wattananupong; Nirush Lertprasertsuke; Usanee Vinitketkumnuen
Journal:  BMC Cancer       Date:  2005-10-04       Impact factor: 4.430

2.  Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells.

Authors:  R Wild; M Dhanabal; T A Olson; S Ramakrishnan
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

3.  Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis.

Authors:  Eric M George; Huiling Liu; Grant G Robinson; Fakhri Mahdi; Eddie Perkins; Gene L Bidwell
Journal:  Vasc Cell       Date:  2015-01-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.